ALLIANCEBERNSTEIN HOLDING L.P. (AB)
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
📉 **NEGATIVE** • Low confidence analysis (51%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (21%) **Content type:** Clinical